Ed Hallen - Sep 11, 2025 Form 4 Insider Report for Klaviyo, Inc. (KVYO)

Role
Director, 10%+ Owner
Signature
/s/ Landon Edmond, Attorney-in-Fact
Stock symbol
KVYO
Transactions as of
Sep 11, 2025
Transactions value $
$0
Form type
4
Date filed
9/12/2025, 06:08 PM
Previous filing
Sep 20, 2023
Next filing
Sep 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hallen Ed Director, 10%+ Owner C/O KLAVIYO, INC. 125 SUMMER STREET, 6TH FLOOR, BOSTON /s/ Landon Edmond, Attorney-in-Fact 2025-09-12 0001991125

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KVYO Series A Common Stock Conversion of derivative security +990K 990K Sep 11, 2025 Direct F1
transaction KVYO Series A Common Stock Gift $0 -990K -100% $0.00 0 Sep 11, 2025 Direct F2
transaction KVYO Series A Common Stock Gift $0 +200K $0.00 200K Sep 11, 2025 By Hodgkins Trust F2, F3
transaction KVYO Series A Common Stock Gift $0 +790K $0.00 790K Sep 11, 2025 By Hodgkins LLC F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KVYO Series B Common Stock Conversion of derivative security $0 -990K -3% $0.00 32M Sep 11, 2025 Series A Common Stock 990K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
F2 On September 11, 2025, the Reporting Person transferred 200,000 shares of Series A Common Stock to Hodgkins Trust and 790,000 shares of Series A Common Stock to Hodgkins LLC for estate planning purposes, in each case for no consideration.
F3 Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
F4 Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.